Summary
- Green light received from the FDA to initiate a phase 3 study using buntanetap for the treatment of early-stage Parkinson's Disease patients.
- The global Parkinson's Disease market is expected to reach $8.38 billion by end of 2026.
- Potential to receive clearance to initiate a phase 3 study using buntanetap for the treatment of patients with Alzheimer's Disease if end of phase 2 meeting goes well.
- Other drugs in the pipeline include ANVS301 for advanced Alzheimer's Disease/dementia and ANVS405 for traumatic brain injury and stroke.
For further details see:
Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look